Literature DB >> 22931898

A new standardized format for reporting hearing outcome in clinical trials.

Richard K Gurgel1, Robert K Jackler, Robert A Dobie, Gerald R Popelka.   

Abstract

The lack of an adequate standardized method for reporting level of hearing function in clinical trials has hampered the ability of investigators to draw comparisons across studies. Variability in data reported and presentation format inhibits meta-analysis and makes it impossible to accumulate the large patient cohorts needed for statistically significant inference. Recognizing its importance to the field and after a widely inclusive discussion, the Hearing Committee of the American Academy of Otolaryngology-Head and Neck Surgery endorsed a new minimal standard for reporting hearing results in clinical trials, consisting of a scattergram relating average pure-tone threshold to word recognition score. Investigators remain free to publish their hearing data in any format they believe is interesting and informative, as long as they include the minimal data set to facilitate interstudy comparability.

Entities:  

Mesh:

Year:  2012        PMID: 22931898     DOI: 10.1177/0194599812458401

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  85 in total

1.  The impact of MRI steady-state sequences as an additional assessment modality in vestibular schwannoma patients after LINAC stereotactic radiotherapy or radiosurgery.

Authors:  Julian P Sauer; Thomas M Kinfe; Bogdan Pintea; Andreas Schäfer; Jan P Boström
Journal:  Strahlenther Onkol       Date:  2018-05-23       Impact factor: 3.621

2.  Hearing Outcomes Reporting in Lateral Skull Base Surgery.

Authors:  Geoffrey C Casazza; Christian A Bowers; Richard K Gurgel
Journal:  J Neurol Surg B Skull Base       Date:  2018-12-05

3.  Minimal Reporting Standards for Active Middle Ear Hearing Implants.

Authors:  Hannes Maier; Uwe Baumann; Wolf-Dieter Baumgartner; Dirk Beutner; Marco D Caversaccio; Thomas Keintzel; Martin Kompis; Thomas Lenarz; Astrid Magele; Torsten Mewes; Alexander Müller; Tobias Rader; Torsten Rahne; Sebastian P Schraven; Burkard Schwab; Georg Mathias Sprinzl; Bernd Strauchmann; Ingo Todt; Thomas Wesarg; Barbara Wollenberg; Stefan K Plontke
Journal:  Audiol Neurootol       Date:  2018-09-07       Impact factor: 1.854

4.  Histopathologic Characteristics of Internal Auditory Canal Diverticula.

Authors:  Thomas Muelleman; Anne K Maxwell; Ivan Lopez; Fred Linthicum; Akira Ishiyama; Luke Ledbetter; James Lin; Hinrich Staecker; Mia Miller
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

5.  Assessment of Hearing Aid Benefit Using Patient-Reported Outcomes and Audiologic Measures.

Authors:  James R Dornhoffer; Ted A Meyer; Judy R Dubno; Theodore R McRackan
Journal:  Audiol Neurootol       Date:  2020-04-02       Impact factor: 1.854

6.  High-Frequency Conductive Hearing following Total Drum Replacement Tympanoplasty.

Authors:  Marc D Polanik; Danielle R Trakimas; Nicole L Black; Jeffrey T Cheng; Elliott D Kozin; Aaron K Remenschneider
Journal:  Otolaryngol Head Neck Surg       Date:  2020-02-25       Impact factor: 3.497

7.  Hearing Outcomes after Middle Fossa or Retrosigmoid Craniotomy for Vestibular Schwannoma Tumors.

Authors:  Eric P Wilkinson; Daniel S Roberts; Adam Cassis; Marc S Schwartz
Journal:  J Neurol Surg B Skull Base       Date:  2016-02-13

8.  Treatment Outcomes for Single Modality Management of Glomus Jugulare Tumors With Stereotactic Radiosurgery.

Authors:  Mitchell R Dobberpuhl; Stevie Maxwell; Jonathan Feddock; William St Clair; Matthew L Bush
Journal:  Otol Neurotol       Date:  2016-10       Impact factor: 2.311

9.  Speech audiometry and data logging in CI patients : Implications for adequate test levels.

Authors:  M Hey; T Hocke; P Ambrosch
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

10.  Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Authors:  Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.